Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.
Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.
复制标题
胸部放疗 (TRT) 改善了寡转移性和多转移性广泛期小细胞肺癌的生存率
DOI：
10.1038/s41598-017-09775-0
复制
发表时间：
2017-08-23
影响因子：
4.6
通讯作者：
Wang P
中科院分区：
文献类型：
--
作者：
Xu LM;Cheng C;Kang M;Luo J;Gong LL;Pang QS;Wang J;Yuan ZY;Zhao LJ;Wang P
目前尚无关于少转移或多转移广泛期小细胞肺癌（ES-SCLC）胸部放疗（TRT）对总生存期（OS）的影响的研究。在一组270例ES-SCLC病例的回顾性研究中，78例（28.9%）患者有寡转移，192例（71.1%）有多转移，其中51例（65.4%）寡转移患者和93例（51.6%）多转移患者接受了TRT。使用倾向评分匹配（PSM）。寡转移和多转移患者的2年OS、无进展生存期（PFS）和局部控制（LC）分别为22.8%和4.5%（p 0.001）、12.0%和3.8%（p 0.001）以及36.7%和6.1%（p 0.001）。化疗+放疗和单纯化疗的寡转移患者的2年OS分别为25.2%和12.7%（p = 0.002），而多转移患者的2年OS分别为10.0%和6.8%（p = 0.030）。对于接受放疗的寡转移和多转移患者，估计的生存风险比分别为2.9和1.7。多转移组的LC较低（6.1% vs. 36.7%，（p 0.001）），由于多转移患者接受低剂量方案的受累部位放疗。TRT改善了寡转移和多转移患者的OS。我们的研究表明，积极的TRT可能是一个合适的附加化疗时，治疗少转移和多发转移ES-SCLC患者。
There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p 0.001), 12.0% and 3.8% (p 0.001), and 36.7% and 6.1% (p 0.001), respectively. The 2-year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in contrast to 10.0% and 6.8% (p = 0.030) in polymetastatic patients. The estimated hazard ratios for survival were 2.9 and 1.7 for both oligometastatic and polymetastatic patients with radiotherapy. The polymetastatic group has a lower LC (6.1% v.s. 36.7%, (p 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low dose schemas. TRT improved OS of patients with oligometastases and polymetastases. Our study demonstrated that aggressive TRT might be a suitable addition of chemotherapy when treating ES-SCLC patients with oligometastases and polymetastases.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
5.8
作者：
Grilley-Olson, Juneko E.;Keedy, Vicki L.;Stinchcombe, Thomas E.
通讯作者：
Stinchcombe, Thomas E.
DOI：
10.6004/jnccn.2013.0011
发表时间：
2013-01-01
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
Kalemkerian GP;Akerley W;Bogner P;Borghaei H;Chow LQ;Downey RJ;Gandhi L;Ganti AK;Govindan R;Grecula JC;Hayman J;Heist RS;Horn L;Jahan T;Koczywas M;Loo BW Jr;Merritt RE;Moran CA;Niell HB;O'Malley J;Patel JD;Ready N;Rudin CM;Williams CC Jr;Gregory K;Hughes M;National Comprehensive Cancer Network
通讯作者：
National Comprehensive Cancer Network
影响因子：
6.2
作者：
Byers LA;Rudin CM
通讯作者：
Rudin CM
影响因子：
20.4
作者：
De Ruysscher, Dirk;Wanders, Rinus;Lambin, Philippe
通讯作者：
Lambin, Philippe